159 related articles for article (PubMed ID: 36326180)
41. The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma.
Chen J; He Q; Liu W; Li Y; Zhuang W
Clin Interv Aging; 2020; 15():431-439. PubMed ID: 32256058
[TBL] [Abstract][Full Text] [Related]
42. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.
Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Tsushima E; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
Int J Urol; 2021 Apr; 28(4):369-375. PubMed ID: 33314387
[TBL] [Abstract][Full Text] [Related]
43. Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach.
Hall ME; Bhindi B; Luckenbaugh AN; Laviana AA; Moses KA; Satkunasivam R; Rini B; Klaassen Z; Wallis CJD
Cancer Causes Control; 2021 Jul; 32(7):675-680. PubMed ID: 33963938
[TBL] [Abstract][Full Text] [Related]
44. Shifting role of cytoreductive nephrectomy according to type of systemic therapy: A nationwide cohort study.
Choi SY; Ha MS; Lee JW; Kim JH; Kim JH; Chi BH; Kim JW; Chang IH; Kim TH; Myung SC
Asian J Surg; 2023 Jan; 46(1):328-336. PubMed ID: 35450758
[TBL] [Abstract][Full Text] [Related]
45. Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era.
Lyon TD; Gershman B; Shah PH; Thompson RH; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
Urol Oncol; 2018 Nov; 36(11):499.e1-499.e7. PubMed ID: 30228096
[TBL] [Abstract][Full Text] [Related]
46. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
De Gobbi A; Biasoni D; Catanzaro M; Nicolai N; Piva L; Stagni S; Torelli T; Procopio G; Verzoni E; Grassi P; Colecchia M; Paolini B; Spreafico C; Marchianò A; Salvioni R
Tumori; 2018 Oct; 104(5):388-393. PubMed ID: 28085177
[TBL] [Abstract][Full Text] [Related]
47. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
[TBL] [Abstract][Full Text] [Related]
48. Clear Cell Renal Cell Carcinoma: Machine Learning-Based Quantitative Computed Tomography Texture Analysis for Prediction of Fuhrman Nuclear Grade.
Bektas CT; Kocak B; Yardimci AH; Turkcanoglu MH; Yucetas U; Koca SB; Erdim C; Kilickesmez O
Eur Radiol; 2019 Mar; 29(3):1153-1163. PubMed ID: 30167812
[TBL] [Abstract][Full Text] [Related]
49. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting.
Ljungberg B; Sundqvist P; Lindblad P; Kjellman A; Thorstenson A; Hellström M; Kröger Dahlin BI; Thomasson M; Harmenberg U; Lundstam S
Scand J Urol; 2020 Dec; 54(6):487-492. PubMed ID: 32897123
[TBL] [Abstract][Full Text] [Related]
50. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study.
Okita K; Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
Urol Oncol; 2021 Dec; 39(12):836.e11-836.e17. PubMed ID: 34544649
[TBL] [Abstract][Full Text] [Related]
51. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.
Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
Cancer Med; 2019 Jul; 8(7):3401-3410. PubMed ID: 31070307
[TBL] [Abstract][Full Text] [Related]
52. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).
Marchioni M; Kriegmair M; Heck M; Amiel T; Porpiglia F; Ceccucci E; Campi R; Minervini A; Mari A; Van Bruwaene S; Linares E; Hevia V; Musquera M; D'Anna M; Derweesh I; Bradshaw A; Autorino R; Guruli G; Veccia A; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Palumbo C; Klatte T; Erdem S; Mir MC;
Eur Urol Oncol; 2021 Apr; 4(2):256-263. PubMed ID: 33384274
[TBL] [Abstract][Full Text] [Related]
53. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
[TBL] [Abstract][Full Text] [Related]
54. Machine learning-based prediction of acute kidney injury after nephrectomy in patients with renal cell carcinoma.
Lee Y; Ryu J; Kang MW; Seo KH; Kim J; Suh J; Kim YC; Kim DK; Oh KH; Joo KW; Kim YS; Jeong CW; Lee SC; Kwak C; Kim S; Han SS
Sci Rep; 2021 Aug; 11(1):15704. PubMed ID: 34344909
[TBL] [Abstract][Full Text] [Related]
55. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
[TBL] [Abstract][Full Text] [Related]
56. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
[TBL] [Abstract][Full Text] [Related]
57. Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.
Gershman B; Moreira DM; Boorjian SA; Lohse CM; Cheville JC; Costello BA; Leibovich BC; Thompson RH
Eur Urol; 2016 Jan; 69(1):84-91. PubMed ID: 26044802
[TBL] [Abstract][Full Text] [Related]
58. Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era.
Tatsugami K; Shinohara N; Kondo T; Yamasaki T; Eto M; Tsushima T; Terachi T; Naito S;
Int J Urol; 2015 Aug; 22(8):736-40. PubMed ID: 25988793
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Yoshino M; Ishihara H; Nemoto Y; Nakamura K; Nishimura K; Tachibana H; Fukuda H; Toki D; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Jpn J Clin Oncol; 2022 Oct; 52(10):1208-1214. PubMed ID: 35780441
[TBL] [Abstract][Full Text] [Related]
60. A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study.
Hu Y; Xu S; Qi Q; Wang X; Meng J; Zhou J; Hao Z; Liang Q; Feng X; Liang C
Front Public Health; 2022; 10():989566. PubMed ID: 36276376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
